Fig. 8: Prediction of clinical groups and symptoms across APOE genotyping groups.

a The AUCs for APOE ε4 carriers versus APOE ε4 noncarriers for the 5-fold cross-validation in NA (42 APOE ε4 carriers versus 43 APOE ε4 noncarriers), MCI (39 APOE ε4 carriers versus 39 APOE ε4 noncarriers), and AD groups (39 APOE ε4 carriers versus 33 APOE ε4 noncarriers), respectively. b Functional connectivity was not able to estimate the MMSE scores in the elderly participants across two APOE genotypes (N = 235). c Functional connectivity was also not able to estimate the LIMM scores in the cross-genetic cohort (N = 235).